- Stocks
- Healthcare
- NASDAQ: INCY

Price (delayed)

$70.81

Market cap

$15.79B

P/E Ratio

46.28

Dividend/share

N/A

EPS

$1.53

Enterprise value

$12.87B

Incyte Corp is an American pharmaceutical company based in Alapocas, Delaware. The company was founded in Palo Alto, California in 1991 and went public in 1993. Incyte has one drug,

INCY's equity is up by 16% year-on-year and by 3.4% since the previous quarter

Incyte's revenue has increased by 14% YoY

INCY's P/E is 75% above its last 4 quarters average of 26.5

INCY's EPS has shrunk by 64% YoY and by 61% QoQ

What are the main financial stats of INCY

Market
Valuations
Earnings

Shares outstanding

222.97M

Market cap

$15.79B

Enterprise value

$12.87B

Price to earnings (P/E)

46.28

Price to book (P/B)

3.6

Price to sales (P/S)

4.63

EV/EBIT

24.2

EV/EBITDA

21.46

EV/Sales

3.79

Revenue

$3.39B

EBIT

$531.78M

EBITDA

$599.64M

Free cash flow

$892.11M

Per share
Balance sheet
Liquidity

EPS

$1.53

Free cash flow per share

$4.02

Book value per share

$19.64

Revenue per share

$15.29

TBVPS

$25.03

Total assets

$5.84B

Total liabilities

$1.47B

Debt

$33.26M

Equity

$4.37B

Working capital

$2.94B

Debt to equity

0.01

Current ratio

3.54

Quick ratio

3.36

Net debt/EBITDA

-4.87

Margins
Efficiency
Dividend

EBITDA margin

17.7%

Gross margin

93.9%

Net margin

10%

Operating margin

17.1%

Return on assets

6.3%

Return on equity

8.2%

Return on invested capital

33.4%

Return on capital employed

11.4%

Return on sales

15.7%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Incyte stock price performed over time

Intraday

0.83%

1 week

-4.59%

1 month

-7.57%

1 year

-9.75%

YTD

-11.84%

QTD

-11.84%

How have Incyte's revenue and profit performed over time

Revenue

$3.39B

Gross profit

$3.19B

Operating income

$579.44M

Net income

$340.66M

Gross margin

93.9%

Net margin

10%

The net margin has dropped by 69% year-on-year and by 62% since the previous quarter

INCY's net income has dropped by 64% year-on-year and by 61% since the previous quarter

Incyte's revenue has increased by 14% YoY

INCY's operating margin is down by 13% year-on-year and by 10% since the previous quarter

What is Incyte's growth rate over time

What is Incyte stock price valuation

P/E

46.28

P/B

3.6

P/S

4.63

EV/EBIT

24.2

EV/EBITDA

21.46

EV/Sales

3.79

INCY's P/E is 75% above its last 4 quarters average of 26.5

INCY's EPS has shrunk by 64% YoY and by 61% QoQ

The stock's price to book (P/B) is 47% less than its 5-year quarterly average of 6.8 and 12% less than its last 4 quarters average of 4.1

INCY's equity is up by 16% year-on-year and by 3.4% since the previous quarter

INCY's P/S is 37% below its 5-year quarterly average of 7.3 and 9% below its last 4 quarters average of 5.1

Incyte's revenue has increased by 14% YoY

How efficient is Incyte business performance

The ROE has plunged by 73% YoY and by 63% from the previous quarter

INCY's return on assets has dropped by 72% year-on-year and by 63% since the previous quarter

The ROIC has decreased by 25% YoY and by 2.9% from the previous quarter

INCY's ROS is down by 18% YoY and by 9% QoQ

What is INCY's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for INCY.

How did Incyte financials performed over time

INCY's total liabilities is up by 26% year-on-year and by 15% since the previous quarter

Incyte's total assets has increased by 18% YoY and by 6% from the previous quarter

The debt is 99% smaller than the equity

INCY's equity is up by 16% year-on-year and by 3.4% since the previous quarter

The debt is down by 2.9% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.